Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome

NCT01237769 | Unknown Phase 4

• 1 other identifier: 003
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

In recent years emphasis has been given to investigate the role of vitamin D in areas beyond bone metabolism and maintenance of calcium homeostasis. Thus, vitamin D deficiency has been associated with risk factors for the occurrence of cardiovascular disease as well as with overall mortality.In addition, there are indications that a large proportion of the population (up to 50%) is vitamin D deficient. The measurement of vitamin 25 (OH) D3 levels is the best way to estimate the vitamin D actual reserves. It is worth mentioning that elevated levels of parathyroid hormone (PTH) \[5\] and reduced levels of 1,25 (OH)2 vitamin D3 (calcitriol have also been associated with cardiovascular disease. The metabolic syndrome is a sum of risk factors for cardiovascular disease and is found in approximately 25% of the Greek population.There are a lot of data linking low vitamin D levels with the metabolic syndrome as a whole as well as with its individual characteristics. Specifically, vitamin D deficiency has been associated with increased incidence of hypertension, dyslipidemia, obesity, inflammation and dysglycemia. Many studies have explored the effect of giving vitamin D supplements on the risk factors associated with the metabolic syndrome and the cardiovascular disease. The results of these studies are conflicting and this may partially be due to different doses of vitamin D used. The form of vitamin D most commonly used in these studies is cholecalciferol (vitamin D3. Aim of the study: Determination of the effect of cholecalciferol (VitD3) (2200 IU/day) on metabolic parameters in patients with metabolic syndrome. Endpoints: The primary endpoint will be changes in metabolic syndrome parameters 3 months after starting treatment:

• Waist circumference
• Blood pressure
• Levels of fasting serum triglycerides
• Levels of high-density lipoprotein cholesterol (HDL-C)
• Levels of fasting serum glucose. The secondary endpoints will include changes in:
• The levels of low-density lipoprotein cholesterol (LDL-C) and non-HDL-C
• Subfractions of LDL-C \[average particle size of LDL-C, levels of small dense (sd) LDL-C\]
• Subfractions of HDL-C (levels of small and large particle HDL-C)
• The activity and levels of Lp-PLA2 (lipoprotein-associated phospholipase A2)
• The levels of serum apolipoprotein AI, A-II, AV, B, E, C-II, C-III and lipoprotein (Lp) (a)
• The activity of paraoxonase-1 (PON1)
• The concentration of pre-beta1-HDL
• The levels of hs-CRP (high sensitivity C-reactive protein)
• Oxidative stress as measured by levels of 8-isoprostane in the blood and urine and oxidized LDL (oxLDL)
• Adipokine levels (leptin, adiponectin, visfatin)
• Glucose homeostasis (index HOMA: fasting insulin X fasting glucose/405)
• The levels of glycosylated hemoglobin (HbA1c)
• The levels of 25 (OH) vitamin D3, of 1,25 (OH)2 vitamin D3 and PTH
• The levels of serum electrolytes (Ca, PO4) and the activity of alkaline phosphatase (ALP) in serum. Study population: The investigators will study patients with metabolic syndrome (n = 50 adults) attending the Outpatient Lipid and Obesity clinic at the University Hospital of Ioannina. Diagnosis of the Metabolic Syndrome will be based on the criteria of National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III). All patients will be instructed to exercise and lose weight according to the NCEP-ATP III diet. The participants will be randomized in an open manner into one of the following 2 treatment groups: a) cholecalciferol (VitD3) (2200 IU/day) plus lifestyle measures or b) only lifestyle measures. Recruitment will be completed within one year. The reassessment of the patients will be done 3 months after starting of treatment.

Conditions

Metabolic Syndrome

Keywords

vitamin D; Metabolic syndrome; Hypertension; Dyslipidemia; Dysglycemia; Inflammation

Outcome Measures

Primary Outcomes (1)

• Change in metabolic syndrome incidence 3 months after starting treatment

  Baseline and 3 months

Secondary Outcomes (6)

• Change in levels of fasting glucose

  Baseline and 3 months

• Change in levels of high-density lipoprotein cholesterol (HDL-C)

  Baseline and 3 months

• Change in levels of blood pressure

  Baseline and 3 months

• Changes in serum triglycerides

  Baseline and 3 months

• Changes in levels of low-density lipoprotein cholesterol (LDL-C)

  Baseline and 3 months

Study Arms (2)

Vitamin D

ACTIVE COMPARATOR

All patients will be instructed to exercise and lose weight according to the NCEP-ATP III diet. The participants will be randomized in an open manner into one of the following 2 treatment groups: a) cholecalciferol (VitD3) (2200 IU/day) plus lifestyle measures or b) only lifestyle measures. Recruitment will be completed within one year. The reassessment of the patients will be done 3 months after starting of treatment.

Drug: Vitamin D3

Lifestyle measures

ACTIVE COMPARATOR

Behavioral: Lifestyle advice

Interventions

Vitamin D3 DRUG

2200 IU/day

Also known as: vitamin D

Vitamin D

Lifestyle advice BEHAVIORAL

Diet and exercise

Also known as: Lifestyle measures

Lifestyle measures

Eligibility Criteria

• Age: 16 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with metabolic syndrome (n = 50 adults) attending the Outpatient Lipid and Obesity clinic at the University Hospital of Ioannina. Diagnosis of the Metabolic Syndrome will be based on the criteria of National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III).

You may not qualify if:

• The study will exclude patients with triglyceride levels \>500 mg/dL,
• Diabetes mellitus, hypothyroidism (TSH \>5 IU/mL),
• Primary hyperparathyroidism, hypercalcemia of any cause,
• A history of taking formulations of calcium or vitamin D,
• Alcohol consumption \>3 drinks per day for men and \>2 drinks per day for women and women of childbearing age not taking contraceptive measures.
• Patients with hypertension may be included in the study if their blood pressure is \<140/90 and the antihypertensive treatment remains constant over the past 3 months (no change of antihypertensive medication during the study).
• Finally, patients receiving lipid-lowering medicines or patients who have stopped taking them for less than 4 weeks will be excluded from the study.

Sponsors & Collaborators

• University of Ioannina: lead

Study Sites (1)

Outpatient Lipid Clinic, University Hospital of Ioannina

Ioannina, Ioannina, 45 110, Greece

RECRUITING

Related Publications (2)

• Makariou SE, Elisaf M, Challa A, Tellis C, Tselepis AD, Liberopoulos EN. Effect of combined vitamin D administration plus dietary intervention on oxidative stress markers in patients with metabolic syndrome: A pilot randomized study. Clin Nutr ESPEN. 2019 Feb;29:198-202. doi: 10.1016/j.clnesp.2018.10.004. Epub 2018 Oct 24.

  PMID: 30661687 DERIVED

• Makariou SE, Elisaf M, Challa A, Tentolouris N, Liberopoulos EN. No effect of vitamin D supplementation on cardiovascular risk factors in subjects with metabolic syndrome: a pilot randomised study. Arch Med Sci Atheroscler Dis. 2017 Oct 5;2:e52-e60. doi: 10.5114/amsad.2017.70504. eCollection 2017.

  PMID: 29242845 DERIVED

Related Links

• Related Info

MeSH Terms

Conditions

Metabolic Syndrome; Hypertension; Dyslipidemias; Inflammation

Interventions

Cholecalciferol; Vitamin D

Condition Hierarchy (Ancestors)

Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Vascular Diseases; Cardiovascular Diseases; Lipid Metabolism Disorders; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Cholestenes; Cholestanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Sterols; Secosteroids; Membrane Lipids; Lipids

Study Officials

• Moses Elisaf, MD

  University of Ioannina Medical School

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Moses Elisaf, MD

CONTACT

+302651007509; egepi@cc.uoi.gr

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: November 9, 2010
• First Posted: November 10, 2010
• Study Start: October 1, 2010
• Primary Completion: March 1, 2012
• Study Completion: March 1, 2012
• Last Updated: August 18, 2011

Record last verified: 2010-11

Locations

GR (1)